DexCom, Inc. (DXCM) Cash Flow Statement

The wide fluctuation in OCF/NI, from 1.08 in 2026Q2 to 2.63 in 2026Q1, suggests that working capital swings, not earnings quality, drive the variability. The 2026Q2 dip appears tied to a $97.6M working capital outflow, likely reflecting inventory builds or receivable timing, which may normalize. Investors should monitor whether the elevated OCF/NI in quarters like 2026Q1 (2.63) is sustainable or a one-time benefit from payables management.

The FCF trajectory shows robust growth, with 2026Q1 FCF of $449.0M and 2025Q3 FCF of $579.4M, but 2025Q1 and 2024Q3 saw FCF margins below 10%. This unevenness appears driven by working capital swings, not operational deterioration, as revenue growth remains strong. The 2026Q2 FCF of $184.5M, while lower than the prior quarter, still represents a 14.1% margin, suggesting the underlying business generates solid cash.

The reduction in CapEx/Revenue from 11.2% to 6.5% suggests that Dexcom is past the peak investment phase for G7 capacity, allowing more cash to flow to FCF. However, the absolute CapEx remains elevated at $84.7M in 2026Q2, reflecting ongoing automation investments. This trend supports margin expansion, but investors should watch for any new product cycle that could require a step-up in capital spending.

The large positive working capital contribution in 2026Q1 (likely from payables or collections) reversed in 2026Q2, causing a $312M swing in operating cash flow. This volatility appears tied to channel mix shifts and inventory builds ahead of new product launches. While not alarming, it complicates quarterly comparisons; investors should focus on trailing twelve-month cash flow to smooth these effects.

The resumption of aggressive buybacks, with $603.6M in a single quarter, signals management's confidence in cash generation and undervaluation. However, this deployment reduces cash reserves and may increase leverage if funded with debt. Given the company's healthy balance sheet, the buybacks appear manageable, but investors should monitor the pace against FCF, which was only $184.5M in 2026Q2, suggesting the buyback may be debt-funded.

The cumulative OCF/NI ratio of 1.7 over the period suggests that earnings are more than fully backed by cash, with the excess driven by non-cash charges like D&A and SBC. This divergence is a positive signal, indicating that the company is not relying on aggressive accruals to boost earnings. However, the gap may narrow if working capital outflows persist, so investors should track this trend.